| DORIS Remission | |||||
| Out of all patients (n = 1684) | Proportion of patients fulfilling remission | Prednisone dose (mg/day) <5 | Physician’s global assessment (Scale 0–3) <0.5 | Clinicala SLEDAI-2K = 0 | |
| At week 52 (n = 1684) | 142 (8.4%) | 647 (38.4%) | 541 (32.1%) | 484 (28.7%) | |
| All visits (n = 23 756) | 1012 (4.3%) | 8118 (34.4%) | 5284 (22.4%) | 4762 (20.2%) | |
| LLDAS | |||||
| Proportion of patients fulfilling LLDAS | Prednisone dose (mg/day) ≤7.5 | Physician’s global assessment (Scale 0–3) ≤1 | SLEDAI-2K ≤4 with no activity in major organ systemsb | No new features of lupus disease activityc compared with the previous assessment | |
| At week 52 (n = 1684) | 294 (17.5%) | 818 (48.6%) | 930 (55.2%) | 726 (43.1%) | 1353 (80.3%) |
| All visits (n = 23 756) | 2529 (10.7%) | 10 399 (44.1%) | 10 523 (44.6%) | 7544 (40.0%) | 18 759 (79.6%) |
| DORIS Remission | |||||
| Out of all patients (n = 1684) | Proportion of patients fulfilling remission | Prednisone dose (mg/day) <5 | Physician’s global assessment (Scale 0–3) <0.5 | Clinicala SLEDAI-2K = 0 | |
| At week 52 (n = 1684) | 142 (8.4%) | 647 (38.4%) | 541 (32.1%) | 484 (28.7%) | |
| All visits (n = 23 756) | 1012 (4.3%) | 8118 (34.4%) | 5284 (22.4%) | 4762 (20.2%) | |
| LLDAS | |||||
| Proportion of patients fulfilling LLDAS | Prednisone dose (mg/day) ≤7.5 | Physician’s global assessment (Scale 0–3) ≤1 | SLEDAI-2K ≤4 with no activity in major organ systemsb | No new features of lupus disease activityc compared with the previous assessment | |
| At week 52 (n = 1684) | 294 (17.5%) | 818 (48.6%) | 930 (55.2%) | 726 (43.1%) | 1353 (80.3%) |
| All visits (n = 23 756) | 2529 (10.7%) | 10 399 (44.1%) | 10 523 (44.6%) | 7544 (40.0%) | 18 759 (79.6%) |
Data are presented as numbers of patients fulfilling the criterion per total number of patients in the respective category (%) in the pooled BLISS datasets. Standard maintenance doses of immunosuppressive drugs and approved biological agents were allowed and incorporated.
Serological items (anti-double stranded DNA positivity, or low C3 or C4) excluded.
SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever).
Using SLEDAI-2K.
DORIS: Definitions Of Remission In SLE; LLDAS: lupus low disease activity state; SLEDAI-2K: SLEDAI 2000.
| DORIS Remission | |||||
| Out of all patients (n = 1684) | Proportion of patients fulfilling remission | Prednisone dose (mg/day) <5 | Physician’s global assessment (Scale 0–3) <0.5 | Clinicala SLEDAI-2K = 0 | |
| At week 52 (n = 1684) | 142 (8.4%) | 647 (38.4%) | 541 (32.1%) | 484 (28.7%) | |
| All visits (n = 23 756) | 1012 (4.3%) | 8118 (34.4%) | 5284 (22.4%) | 4762 (20.2%) | |
| LLDAS | |||||
| Proportion of patients fulfilling LLDAS | Prednisone dose (mg/day) ≤7.5 | Physician’s global assessment (Scale 0–3) ≤1 | SLEDAI-2K ≤4 with no activity in major organ systemsb | No new features of lupus disease activityc compared with the previous assessment | |
| At week 52 (n = 1684) | 294 (17.5%) | 818 (48.6%) | 930 (55.2%) | 726 (43.1%) | 1353 (80.3%) |
| All visits (n = 23 756) | 2529 (10.7%) | 10 399 (44.1%) | 10 523 (44.6%) | 7544 (40.0%) | 18 759 (79.6%) |
| DORIS Remission | |||||
| Out of all patients (n = 1684) | Proportion of patients fulfilling remission | Prednisone dose (mg/day) <5 | Physician’s global assessment (Scale 0–3) <0.5 | Clinicala SLEDAI-2K = 0 | |
| At week 52 (n = 1684) | 142 (8.4%) | 647 (38.4%) | 541 (32.1%) | 484 (28.7%) | |
| All visits (n = 23 756) | 1012 (4.3%) | 8118 (34.4%) | 5284 (22.4%) | 4762 (20.2%) | |
| LLDAS | |||||
| Proportion of patients fulfilling LLDAS | Prednisone dose (mg/day) ≤7.5 | Physician’s global assessment (Scale 0–3) ≤1 | SLEDAI-2K ≤4 with no activity in major organ systemsb | No new features of lupus disease activityc compared with the previous assessment | |
| At week 52 (n = 1684) | 294 (17.5%) | 818 (48.6%) | 930 (55.2%) | 726 (43.1%) | 1353 (80.3%) |
| All visits (n = 23 756) | 2529 (10.7%) | 10 399 (44.1%) | 10 523 (44.6%) | 7544 (40.0%) | 18 759 (79.6%) |
Data are presented as numbers of patients fulfilling the criterion per total number of patients in the respective category (%) in the pooled BLISS datasets. Standard maintenance doses of immunosuppressive drugs and approved biological agents were allowed and incorporated.
Serological items (anti-double stranded DNA positivity, or low C3 or C4) excluded.
SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever).
Using SLEDAI-2K.
DORIS: Definitions Of Remission In SLE; LLDAS: lupus low disease activity state; SLEDAI-2K: SLEDAI 2000.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
